BJMO - 2024, issue Special, june 2024
James Collins PhD, T. Feys MBA, MSc
There continues to be a large unmet medical need for non-small cell lung cancer (NSCLC) patients in whom immunotherapy and chemotherapy have failed.1 Several studies have suggested that antibody-drug conjugates (ADCs) hold promise for the treatment of these patients. This mini-review will briefly summarise the available data on the use of TROP-2 directed ADCs in this setting.
Read moreBJMO - 2024, issue Special, june 2024
James Collins PhD
Lung cancer is a leading cause of cancer mortality for both men and women. Guidelines for the clinical staging and prognosis of lung cancer are under constant revision due to advancement and generation of new data. At the European Lung Cancer Congress 2024 in Prague, the 9th TNM classification for lung cancer was discussed by Dr. Ramon Rami-Porta from the Hospital Universitari Mútua Terrassa, Spain.1
Read moreBJMO - 2024, issue Special, februari 2024
James Collins PhD, T. Feys MBA, MSc
With respect to hormone receptor positive (HR+) breast cancer, SABCS 2023 featured subgroup analyses of the CheckMate 7FL and KEYNOTE-756 trials evaluating perioperative nivolumab or pembrolizumab in patients with early-stage disease.1,2 Also in early-stage HR+ breast cancer, the final invasive disease free survival (iDFS) analysis of the NATALEE trial was presented evaluating adjuvant ribociclib added to ET.3 In metastatic HR+/HER2- breast cancer, datopotamab deruxtecan was shown to delay disease progression in pre-treated patients.4 In the first line treatment for advanced HR+/HER2- breast cancer, SABCS 2023 featured the overall survival (OS) analysis of the MONARCH-3 trial, while INAVO120 demonstrated a progression-free survival (PFS) benefit for the addition of the PI3Kα inhibitor inavolisib to palbociclib and fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.5
Read moreBJMO - 2023, issue Special, february 2023
James Collins PhD, T. Feys MBA, MSc
The skin cancer session of the 25th annual meeting of The Belgian Society for Medical Oncology highlighted recent advances in the treatment of patients with melanoma and other skin cancers. Beginning this session, Prof. Dr. Vibeke Kruse (VITAZ – AZ Nikolaas, Sint-Niklaas) discussed adjuvant and neoadjuvant treatments for melanoma. Subsequently, Prof. Dr. Oliver Bechter (University Hospitals Leuven, Leuven) outlined recent findings in metastatic melanoma. Prof. Dr. Jean-Francois Baurain (Cliniques Universitaires St Luc, Brussels) followed up with a ‘survival guide’ for medical oncologists dealing with non-melanoma skin cancer. Dr. Tess van Meerhaeghe (Hôpital Erasme, Cliniques Universitaires de Bruxelles, Brussels) closed the session with an overview of immune checkpoint inhibitors in kidney transplant recipients.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
